Page 93 2011 Highlights • Versus 2010, revenue growth of 9% drives 23% increase in adjusted operating income • Adjusted EPS expands 29% to all-time high of $1.02 Net Sales Adjusted Operating $1.02 Adjusted EPS $2,622 $2,643 $2,739 $2,061 $2,622 $2,864 Net Sales $88 $87 $72 $59 $147 $181 Adjusted Operating Income $0.12 $0.27 $0.21 $0.13 $0.79 $1.02 ($ millions) ($ millions) Page 94 2011 Highlights • Each platform contributed to our year over year operating income growth • Record OI achieved in Specialty and POD • Ten quarters of double-digit adjusted EPS expansion POD PP&SSpecialty Platform ROS%* 0.6% 1.5% 3.2% 4.3% 5.3% 8.4% 8.0% 2.9% 2.6% 3.0% 3.5% 4.0% 4.6% 5.6% 6.7% 5.5% 6.1% 3.1% 5.0% 7.0% 7.2% $20 $19 $22 $28 $25 $42 $56 O p e ra ti n g I n co m e POD $76 $64 $66 $31 $33 $54 $62 O p e ra ti n g In co m e PP&S $5 $13 $31 $46 $46 $87 $89 O p e ra ti n g I n co m e Specialty Platform *ROS% is defined as adjusted operating income % of revenue ($ millions) Page 95 2011 Highlights • Continued portfolio repositioning � Sale of SunBelt equity investment � Acquisition of specialty companies ColorMatrix and Uniplen • World-class working capital of 9.6% maintained while improving on-time delivery to 94%improving on-time delivery to 94% 81% 87% 88% 95% 93% 92% 94% 2005 2006 2007 2008 2009 2010 2011 14.3% 16.2% 14.4% 18.9% 11.7% 9.6% 9.6% 2005 2006 2007 2008 2009 2010 2011 On-Time Delivery Working Capital % of Sales Page 96 First Quarter 2012 Highlights • Revenues increased 9% over Q1 2011 to a new quarterly record • Adjusted EPS increased 12% $0.26 $0.29 Q1 2011 Q1 2012 Adjusted EPS • Adjusted EPS increased 12% over prior year • All platforms delivered double-digit operating income growth Q1 2011 Q1 2012 $25.2 $14.7 $29.1 $17.8 $16.7 Specialty PP&S POD Q1 2011 Q1 2012 Adjusted Operating Income $14.3 ($ millions) Page 97 • Total Debt at 3/31/12 Less: Cash Net Debt • Available Liquidity $706 186 $520 $300 $360 $250 $300 $350 $400 $450 Debt Maturities As of March 31, 2012 ($ millions) Debt Maturities & Liquidity Summary – 3/31/12 • Available Liquidity Cash ABL Availability Total Liquidity • Net Debt / EBITDA* = 1.9x $186 156 $342 *Adjusted EBITDA TTM Pro forma for ColorMatrix $50 $300 $0 $50 $100 $150 $200 $250 2015 2017 2020 Page 98 • Repurchased 6 million shares in 2011 Share Share RepurchaseRepurchase • Introduced a quarterly dividend in Q1 2011 and increased in Q1 DividendsDividends • Expanding our sales, marketing, and technical capabilities is top Organic Organic GrowthGrowth • Targets that expand our: • Specialty offering • End market presence AcquisitionsAcquisitions Use of Cash Current Cash Balance = $186M Net Debt / EBITDA* = 1.9X • 7.9 million shares remain available for repurchase under the current authorization increased in Q1 2012 • Objective of maintaining and growing capabilities is top priority • Investing in operational and LSS initiatives • CAPEX • End market presence • Geographic footprint • Synergy opportunities • Adjacent material solutions *Adjusted EBITDA TTM Pro forma for ColorMatrix Page 99 Page 100

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number reducing risk of change • Non-phthalate and formulated without animal- derived substances • Available for use in a wide range of polymers including polyolefins, styrenics, polycarbonate and alloys, polyester, POM • Functionality can be combined with colorants into convenient combination concentrates and ready-to-use formulations REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request FUNCTIONALITY TARGET APPLICATIONS DRUG DELIVERY DEVICES SYRINGES & NEEDLES DIAGNOSTICS CATHETERS Clarifying PP Sorbitol-free for transparent applications with reduced migration and improved thermal stability     Lubricant— permanent/ non-migrating Fast acting reduction in friction for wide variety of polymers such as PP, ABS, POM, PC    Protection from UV in transparent applications for PP, PE, PETG, COP UV blocking in 290-450nm with no impact on clarity; can be combined with colors (e.g., amber)   Antistatic ready-to- use solution for PP, ABS, PC/ABS Permanent/non-migrating; fast decay time independent of % relative humidity  Gamma/e-beam sterilization protection of the polymer Preserving the properties of PP and COC/COP; reduction in yellowing using Color Compensation Technology (CCT)    Reduced material consumption/cycle time—nucleation Fast acting new generation nucleant for PE and PP; improved thermal and mechanical properties allows wall thinning; reduction of tolerance/dimensional problems between different colors    Laser marking replacing ink printing/labels Solvent-free, high-speed identification for Nd/YAG laser for PE,PP, ABS, PC, POM     Antioxidants for PE, PP, TPE Thermal protection during converting/downstream sterilization    Brand protection/ anticounterfeit Covert and non-covert systems   Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal- derived substances • Available for use in a wide range of polymers including polyolefins, styrenics, polycarbonate and alloys, polyester, POM • Functionality can be combined with colorants into convenient combination concentrates or formulations REGULATORY SUPPORT • Pre-tested raw materials: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request FUNCTIONALITY TARGET APPLICATIONS EBM/IBM CONTAINERS CLOSURES FILM COMBINATION DEVICES Clarifying PP Sorbitol-free—possibilities in packaging ocular solutions    Slip/torque reduction Slip for PE, PP films, processing aid, torque reduction for closures   Protection from UV in transparent packaging for PP, PE, PETG, COP UV blocking in 290–450nm with no impact on clarity    Antistatic ready-to-use solution for PE films e.g. for API handling Permanent/non-migrating; fast decay time independent of % relative humidity  Antistatic masterbatch for PE films Cost effective, long-lasting, migrating type but with biological evaluation  Gamma/e-beam sterilization protection of the polymer Preserving the properties of PP and COC/COP. Reduction in yellowing using Color Compensation Technology (CCT)   Reduced material consumption/cycle time/improved properties—nucleation Fast acting new generation nucleant for PE and PP; improved dimensional stability, thermal and mechanical properties    Laser marking replacing ink printing/labels Solvent-free, high-speed identification for Nd/YAG laser    Antiblock for PE/PP film Non-migrating additive system maintaining high gloss and printability  Antioxidants for PE, PP, TPE Thermal protection during converting/ downstream sterilization     Brand protection/ anticounterfeit Range of covert and non-covert systems    Volatiles/odor absorber for PE/PP Physical absorption of a wide range of molecules responsible for odor, VOC and potential extractables/ leachables in plastics   Healthcare use limitations apply—see below.

We are Avient. 6 BETTER TOGETHER: POLYONE AND CLARIANT MASTERBATCH Key Financial Data (1) 2021E Sales $4.6 - $4.7 billion 2021E EBITDA $580 million 2021E Free Cash Flow $280 million 87% of EBITDA from specialty applications (1) As of July 30, 2021 webcast Synergies ($ millions) Three-Year Estimate Administrative $ 20 Sourcing 30 Operational 25 Total Synergies $ 75 7 CLARIANT COST SYNERGIES • On-track to realize $45 million of expected synergies in 2021 – up from previous estimate of $35 million • Relentless focus on guiding principles for acquisition integration: safety first, employee collaboration and exceeding customer expectations • Future revenue synergies in excess of $50 million by 2025 are not part of these estimates and represent additional growth over the long term 8 • Barrier technology • Functional additives • Processing aids • Flame retardants • Light-weighting additives Complementary Technologies • Clariant’s approved formulations and certified facilities • Legacy PolyOne’s leading share in distribution channels Healthcare Solutions • Clariant’s position in SE Asia, Latin America, Germany & Italy • Legacy PolyOne’s position in U.S., Canada and China Regional Strengths • Solutions with Avient’s engineered materials customers • Avient’s distribution channels Segment Cross-selling COMPLEMENTARY TECHNOLOGIES AND CUSTOMERS DRIVE REVENUE SYNERGIES Revenue synergy opportunities in excess of $50MM by 2025 The complementary aspects of our combined businesses are unquestionable. Our free cash flow supports shareholder value creation through investing in R&D for organic growth, completing bolt-on acquisitions, and returning cash to shareholders via our dividend program and opportunistic share repurchases. 30 1. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 31 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 18.5 15.1 15.1 14.0 11.0 10.4 29.5 28.2 23.9 18.7 12.4 12.2 11.1 9.3 9.2 9.2 7.6 7.6 6.0 A vi en t K W R P P G A V Y R P M F U L G C P A L B H X L E C L IF F F M C B N R A S H S C L E M N U N V R K R A C E H U N Median: 11.1xMedian: 14.6x SUMMARY: WHY INVEST IN AVIENT?

Vinod Purayath 12:00 SUMMARY: Jamie Beggs 12:20 AVIENT – AN INVESTMENT IN SUSTAINABLE GROWTH: Bob Patterson 12:30 Q&A 1:00 LUNCH 2Avient Corporation Disclaimer Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L E M N C E A S H S C L Source: Peer data per Bloomberg market data as of December 2, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) 129Avient Corporation 474 644 1,002 107 147 216 467 616 872 2014 2018 2021E R&D / Technical Marketing Sales Commercial Resources Headcount figures all Pro Forma for sale of Designed Structures and Solutions (DSS) and Performance Products and Solutions (PP&S) segments. 2021E data as of October 31, 2021. D is tr ib u tio n A V N T 2021 Expansion Goals With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets.

These include PE, PP, ABS, SAN, PC/ABS, PC, PA6, 66 and 12, cyclic olefins (COP), high performance polymers, and elastomers such as EVA, SEBS, TPU and PEBA. APPLICATION PORTFOLIO DESCRIPTION General use Opaque and transparent colors in PP, PE, COC, ABS, POM, PC, TPU, PEEK, and more Needle hubs and cannulae Opaque and translucent colors evaluated to ISO 6009 Ophthalmic caps and closures 13 standard colors in PE matched to American Academy of Ophthalmology; biologically evaluated to USP standard White pharmaceutical packaging White colorants for PE, HDPE, PP covering solid dose to nasal packaging needs Amber pharmaceutical packaging Pre-tested amber colorants LSR silicones For LSR silicones and transparent color PET/PP (e.g. amber) FUNCTIONALITY ADDITIVE PERFORMANCE UV protection in transparent packaging Blocks UV in 290–450nm for PP, PE, PETG, COP Processing aid/friction reduction Optimizes processing for PE, PP, ABS, POM—non-migrating Nucleation for reduced material consumption/cycle time Improves thermal and mechanical properties of PE and PP and allows wall thinning to support sustainability Clarifying Improves clarity of transparent PP applications with reduced migration and improved thermal stability—sorbitol-free Laser marking/welding Activates the polymer to absorb Nd-YAG laser for fast reliable marking/assembly Gamma/e-beam sterilization Preserves the properties of PP and COP, reduces yellowing and compensates for discoloration Anti-static Reduces static buildup in applications such as films in API handling and inhaler spacers/nebulizers Antioxidant Provides thermal protection during converting/ downstream sterilization Anti-counterfeit/brand protection Covert and non-covert systems SUPPORTING SUSTAINABILITY TARGETS As the need to integrate sustainability in the design of healthcare products is growing, manufacturers of medical devices, diagnostic products and pharmaceutical packaging are looking for materials with a more environmentally friendly profile. The cycle time in injection molding can be reduced (10–15% in PP) to support higher output and less energy consumption.

Maxxam™ Foamable Formulations for Wire & Cable Applications Maxxam™ foamable polypropylene (PP) formulations, both solid and cellular, are developed specifically for wire and cable applications. With their unique properties and benefits, our PP solutions can meet the evolving demands of the industry, providing manufacturers with the tools they need to innovate and excel. Foamable PP formulations for wire and cable applications offer enhanced electrical properties, achieving a high-performance insulation that provides reliability across various applications.

LUBRIONE™ INTERNALLY LUBRICATED FORMULATIONS PRODUCT SELECTION GUIDE PRODUCT DESCRIPTION UNITS TEST METHOD NN–000/15T BLACK NN–20GF– 10GB/13T–2S BLACK NN–30GF/10T WHITE LB8900-0001 30GF/15T NATURAL LB8900-0002 30GF/13T-2S NATURAL LB8900-0003 18T-2S NATURAL ATT–000/5T BLACK AT–000/18T– 2S NATURAL 5209 FPL 20 NATURAL PS–30GF/2S NATURAL LB5210–0237 1B NATURAL PC–10CF/15T BLACK Base Polymer PA 66 PA 66 PA 66 PK PK PK POM POM POM PBT PP PC General Properties Specific Gravity g/cm3 ASTM D792 1.23 1.46 1.47 1.56 1.55 1.33 1.38 1.47 1.51 1.54 1.13 1.31 Molding Shrinkage ASTM D955 Flow % 1.0–2.0 0.20–0.50 0.50–1.0 0.30–0.60 0.20–0.40 1.7–2.3 1.5–2.0 2.0–3.0 2.0–3.0 0.20–0.40 0.10–0.30 0.10–0.30 Water Absoprtion (23°C, 24 hr.) % ASTM D570 0.8 – 0.050–1.0 0.3 0.4 0.4 0.050 – 0.050 – – – Mechanical Properties Tensile Modulus(1) MPa ASTM D638 2650 9650 9790 8050 7380 1250 965 1770 2420 8620 4140 – Tensile Strength(1) (Yield) MPa ASTM D638 61.4 119 122 119 94 47 35 40 45 108 72.4 90 Tensile Elongation(1) (Break) % ASTM D638 3.0–5.0 1.0–3.0 1.5 3 2 35 40 30 26 3 – – Flexural Modulus MPa ASTM D790 2760 6890 6890 7380 6410 1300 1080 1740 1790 6690 4840 5500 Flexural Strength MPa ASTM D790 108 172 214 182 167 55 41.4 62.7 68.3 165 110 130 Coefficient of Friction ASTM D1894 vs.

30

Additionally, new minimum recycled content thresholds will mean that from 2025 there will be a sales ban on PET bottles containing less than 25% recycled plastics, increasing to 30% in 2030.